GlaxoSmithKline is under pressure from shareholders to rein in pay for its incoming chief executive, Emma Walmsley, according to reports. Walmsley is set to take over from Sir Andrew Witty when he ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of ...

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...

Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, ...

Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications. The company, which makes the antacid ...

GlaxoSmithKline Pharmaceuticals reported a notable 16% rise in consolidated net profit for the September quarter, reaching Rs 252 crore. This growth was driven by robust sales and brand performance.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GlaxoSmithKline is under pressure from shareholders to rein in pay for its incoming chief executive, Emma Walmsley, according to reports. Walmsley is set to take over from Sir Andrew Witty when he ...